STEREOTACTIVE ABLATIVE RADIATION THERAPY

December 1, 2014

Stereotactic Ablative Radiation Therapy (RT) is a modern way of delivering high dose of radiation in a short period of time.  Radiation therapy has been given in small doses of daily radiation over a period of 6 to 7 weeks, to give time for the irradiated  normal tissue to repair itself between the treatments, to minimize the acute toxicity from RT.  SART delivers similar dose of RT in just 3 to 5 treatments.

 

This is only possible because of the recent improvements in the technology used to deliver the SART.  The planning process and the computerized mechanism to shape the RT fields have improved significantly, so a high dose of RT can be delivered to the tumor target volume with a sharp fall off of RT dose to the surrounding normal tissue. Equally important, our machine is able to obtain a 3-D C.T. Scan of the tumor region of the patient just before each treatment, so the radiation can be delivered accurately as planned.  

 

With these advances, high dose RT is delivered with limiting the radiation to the normal surrounding organs. Recent presentation at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology reported only about 13% of grade 1-3 side-effects, and no grade 4 or 5 toxicity over 10 years of SART at Cleveland Clinic. SART is a very good option to treat early stage non-small cell lung cancer when surgery is not a plausible option. Although there is no head-to-head comparison of SART to surgical resection in a phase III trial, retrospective studies of SART for lung cancer demonstrated local control of high 80% to low 90% at 2 to 3 years, and low 70% at 5 years, which is comparable to the results of surgical resection.  

 

A prospective phase II clinical trial by The Radiation Therapy Oncology Group, in fact, reported 3 year control in the treated lung tumor of 98%, and control in the treated tumor and involved lung lobe of 91% using SART in medically inoperable patients. Phase III randomized trials comparing SART with surgery in healthy patients who can undergo surgery have been attempted, but they were closed due to poor accrual.

 

It was difficult to ask patients to allow a study to choose for them to either undergo SART involving 3 to 5 outpatient treatments with expected mild side-effects, versus surgical resection to undergo anesthesia and thoracotomy that result in hospitalization with expected chest wall pain and reduction in pulmonary function. At Houston Precision Cancer Center, we have the modern technology, expertise and extensive experience to use SART to treat patients with early stage lung cancer, hepatocellular carcinoma, oligometastases to the lung, liver, and brain.  

Share on Facebook
Share on Twitter
Please reload

Recent Posts
Please reload

Archive
Please reload

CONTACT

!

Your feedback is important. If this

is an urgent matter, please contact your clinic. For all other inquiries, please...

QUICK LINKS

  • Facebook Social Icon
  • Twitter Social Icon
  • Instagram Social Icon
  • LinkedIn Social Icon
  • YouTube Social  Icon

The Oncology Consultants Overcoming Cancer

logo is a registered trademark.

Texas Medical Center
2130 W. Holcombe Blvd., 10th Fl.
Houston, TX 77030
Memorial City
925 Gessner Rd., Ste. 600
Houston, TX 77024
Katy
23960 Katy Freeway, Ste. 325
Katy, TX 77494
Sugar Land
16605 Southwest Frwy, Ste. 550
Sugar Land, TX 77479
Greater Heights 
1631 North Loop West, Ste. 410
Houston, TX 77008
Southeast
11920 Astoria Boulevard, Ste. 150
Houston, TX 77089
Willowbrook
13215  Dotson Rd., Ste. 340
Houston, TX 77070
Southwest
7789 Southwest Fwy, Ste. 460
Houston, TX 77074
Pearland
1920 Country Pl. Pwy, Ste. 370
Pearland, TX 77584
Precision Cancer Center
10405 Katy Freeway, Ste. 150E
Houston, TX 77024